Why carry out this study

Sodium glucose co-transporter 2 (SGLT2) inhibitors have been widely studied and used for treating type 2 diabetes mellitus, but little is known about the effects of SGLT2 inhibitors on type 1 diabetes mellitus.

We aimed to determine whether SGLT2 inhibitors change body composition and blood glucose variability.

What was learned from the study?

SGLT2 inhibitors stabilized glycemic variabilities and tended to decrease fat mass; however, we observed a loss in skeletal muscle.

Although SGLT2 inhibitors are novel agents for type 1 diabetes, careful use of SGLT2 inhibitors must be ensured for lean patients with type 1 diabetes.